Camilla Drexler1, Susanne Macher1, Ines Lindenau2, Magdalena Holter3, Martina Moritz1, Tatjana Stojakovic4, Thomas R Pieber5, Peter Schlenke1, Karin Amrein6. 1. Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria. 2. Department for Anesthesiology and Intensive Care, Medical University of Graz, Graz, Austria. 3. Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Austria. 4. University Hospital Graz, Clinical Institute of Medical and Chemical Laboratory Diagnostics, Graz, Austria. 5. Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria. 6. Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria; Thyroid Endocrinology Osteoporosis Institute Dobnig Graz, Jakob-Redtenbachergasse 10, 8010, Graz, Austria. Electronic address: karin.amrein@medunigraz.at.
Abstract
INTRODUCTION: Frequent blood donation often leads to iron deficiency and even anemia but appropriate strategies for detection and prevention are currently not mandatory. At the Medical University of Graz, we conducted a single-center prospective clinical trial to compare oral and IV iron supplementation in iron deficient blood donors including Austrian regular whole blood and platelet apheresis donors. We aimed to determine the difference of transferrin saturation between the treatment groups 8-12 weeks iron administration besides other parameters of iron status and blood count. METHODS:176 healthy male and female blood donors with iron deficiency (ferritin ≤30 ng/mL) were randomized to either a single dose of IV ferric carboxymaltose (1000 mg, n = 86) or oral iron (II)fumarate (100 tablets of 100 mg [10 per week], n = 90). RESULTS:Between 2014 and 2016, 172 donors (137 women) completed the study; 4 in the oral group were lost to follow-up. At follow-up, median (IQR) transferrin saturation and ferritin were significantly higher in the intravenous group (27 [23-35]%, vs 21.0 [16-32]%; p < 0.001 and 105 [75-145] ng/mL vs 25 [17-34] ng/mL; p < 0.001, respectively) while median (IQR) hemoglobin levels were comparable (IV, 13.6 [13.0-14.4] g/dL vs oral, 13.6 [13.0-14.2] g/dL). The frequency of adverse effects was comparable (38% in both groups) and no serious adverse events occurred. CONCLUSIONS: A single dose of 1000 mg of intravenous iron is highly effective to counteract iatrogenic iron deficiency in blood donors. Oral iron appears to be an acceptable alternative. The assessment of body iron stores should play a key role in maintaining blood donors' health. This trial was registered at www.clinicaltrials.gov as NCT01787526 on February 8, 2013 and at www.clinicaltrialsregister.eu (EudraCT identifier: 2013-000327-14) on September 24, 2013.
RCT Entities:
INTRODUCTION: Frequent blood donation often leads to irondeficiency and even anemia but appropriate strategies for detection and prevention are currently not mandatory. At the Medical University of Graz, we conducted a single-center prospective clinical trial to compare oral and IV iron supplementation in iron deficient blood donors including Austrian regular whole blood and platelet apheresis donors. We aimed to determine the difference of transferrin saturation between the treatment groups 8-12 weeks iron administration besides other parameters of iron status and blood count. METHODS: 176 healthy male and female blood donors with iron deficiency (ferritin ≤30 ng/mL) were randomized to either a single dose of IV ferric carboxymaltose (1000 mg, n = 86) or oral iron (II)fumarate (100 tablets of 100 mg [10 per week], n = 90). RESULTS: Between 2014 and 2016, 172 donors (137 women) completed the study; 4 in the oral group were lost to follow-up. At follow-up, median (IQR) transferrin saturation and ferritin were significantly higher in the intravenous group (27 [23-35]%, vs 21.0 [16-32]%; p < 0.001 and 105 [75-145] ng/mL vs 25 [17-34] ng/mL; p < 0.001, respectively) while median (IQR) hemoglobin levels were comparable (IV, 13.6 [13.0-14.4] g/dL vs oral, 13.6 [13.0-14.2] g/dL). The frequency of adverse effects was comparable (38% in both groups) and no serious adverse events occurred. CONCLUSIONS: A single dose of 1000 mg of intravenous iron is highly effective to counteract iatrogenic iron deficiency in blood donors. Oral iron appears to be an acceptable alternative. The assessment of body iron stores should play a key role in maintaining blood donors' health. This trial was registered at www.clinicaltrials.gov as NCT01787526 on February 8, 2013 and at www.clinicaltrialsregister.eu (EudraCT identifier: 2013-000327-14) on September 24, 2013.
Authors: Susanne Macher; Cornelia Herster; Magdalena Holter; Martina Moritz; Eva Maria Matzhold; Tatjana Stojakovic; Thomas R Pieber; Peter Schlenke; Camilla Drexler; Karin Amrein Journal: Nutrients Date: 2020-05-05 Impact factor: 5.717
Authors: Toby Richards; Christian Breymann; Matthew J Brookes; Stefan Lindgren; Iain C Macdougall; Lawrence P McMahon; Malcolm G Munro; Elizabeta Nemeth; Giuseppe M C Rosano; Ingolf Schiefke; Günter Weiss Journal: Ann Med Date: 2021-12 Impact factor: 4.709
Authors: James Curtis Dring; Alicja Forma; Zuzanna Chilimoniuk; Maciej Dobosz; Grzegorz Teresiński; Grzegorz Buszewicz; Jolanta Flieger; Tomasz Cywka; Jacek Januszewski; Jacek Baj Journal: Nutrients Date: 2021-12-31 Impact factor: 5.717
Authors: Akshay A Shah; Killian Donovan; Claire Seeley; Edward A Dickson; Antony J R Palmer; Carolyn Doree; Susan Brunskill; Jack Reid; Austin G Acheson; Anita Sugavanam; Edward Litton; Simon J Stanworth Journal: JAMA Netw Open Date: 2021-11-01
Authors: Patrick P Torreiter; Susanne Macher; Eva-Maria Matzhold; Bernhard Resch; Philipp Klaritsch; Günther F Körmöczi; Helene Polin; Leopold Neuhold; Marlies Schönbacher; Peter Schlenke; Thomas Wagner Journal: Transfus Med Hemother Date: 2021-01-05 Impact factor: 3.747